Trexquant Investment LP reduced its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 36.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 103,031 shares of the company's stock after selling 58,718 shares during the period. Trexquant Investment LP owned about 0.19% of Stoke Therapeutics worth $1,136,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at approximately $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics during the fourth quarter valued at $124,000. JPMorgan Chase & Co. grew its position in shares of Stoke Therapeutics by 29.2% in the fourth quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after purchasing an additional 4,512 shares during the period. Finally, EntryPoint Capital LLC acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth about $353,000.
Insider Activity
In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by insiders.
Stoke Therapeutics Stock Up 1.7 %
Shares of Stoke Therapeutics stock traded up $0.13 on Tuesday, hitting $7.69. 273,806 shares of the company were exchanged, compared to its average volume of 720,624. The company has a 50-day moving average price of $8.17 and a 200 day moving average price of $10.48. The stock has a market capitalization of $415.86 million, a price-to-earnings ratio of -3.66 and a beta of 1.09. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.
Wall Street Analysts Forecast Growth
STOK has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, Chardan Capital reiterated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $24.67.
Get Our Latest Report on STOK
About Stoke Therapeutics
(
Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Further Reading
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
